Skip to main content
Clinical Trials/NCT00454493
NCT00454493CompletedNot Applicable

The Effect of Fish Oil Supplementation on Endothelial Function, Heart Rate Variability and Intimal Media Thickness of Patients With Coronary Artery Disease

Olive View-UCLA Education & Research Institute1 site in 1 country71 target enrollmentStarted: August 2006Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
71
Locations
1
Primary Endpoint
Percent change in flow-mediated vasodilation by brachial artery ultrasound at 2 months

Study Overview

Brief Summary

The purpose of this study is to investigate whether there is a difference in endothelial function, heart rate variability and carotid intimal media thickness in patients with coronary artery disease who are receiving fish oil therapy.

One hundred patients with established coronary artery disease by coronary angiography will undergo randomization for enrollment in the study. Baseline evaluation will include assessment of brachial artery endothelial function, heart rate variability and carotid intimal media thickness. Evaluation of the endothelial function of the brachial artery will be elucidated by inflation of a blood pressure cuff around the arm for five minutes and measuring blood vessel dynamics after release of the cuff. Heart rate variability will be evaluated by 24 hour holter monitoring and analysis by standard protocol. Carotid intimal media thickness will be evaluated by ultrasound measurements guided by predetermined protocol. Patients will then be randomized to a highly purified fish oil, Omacor, 1 gram twice a day or placebo. Brachial artery ultrasound and holter monitoring will be repeated at 2 months. Carotid ultrasound will be repeated at the end of the study at 12 months.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Established coronary artery disease as determined by coronary angiography within the last 5 years demonstrating at least 50% stenosis in one of the major coronary vessels
  • •Age >18 and <75.

Exclusion Criteria

  • •Baseline fish oil intake ≥1g/day or fish intake >100g/day
  • •Need for urgent or emergent CABG
  • •Contraindication for plavix, aspirin or statin
  • •Gastrointestinal malabsorption syndrome
  • •Oral contraceptive use
  • •Ejection fraction <40%
  • •Underlying atrial or ventricular arrhythmia
  • •History of rheumatoid arthritis

Arms & Interventions

fish oil

Active Comparator

Intervention: Omacor (omega-3-acid ethyl esters) (Drug)

placebo

Placebo Comparator

Intervention: Omacor (omega-3-acid ethyl esters) (Drug)

Outcomes

Primary Outcomes

Percent change in flow-mediated vasodilation by brachial artery ultrasound at 2 months

Time Frame: 2 months

Percent change in flow-mediated vasodilation by brachial artery ultrasound

Percent change in carotid intimal media thickness at 12 months

Time Frame: 2 months

Percent change in carotid intimal media thickness on ultrasound

Change in heart rate variability indices at 2 months

Time Frame: 2 months

Change in heart rate variability indices on holter monitor

Secondary Outcomes

  • Change in QT dispersion interval at 2 months(2 months)

Investigators

Sponsor
Olive View-UCLA Education & Research Institute
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Sheba Meymandi

Director, Cardiovascular Research

University of California, Los Angeles

Study Sites (1)

Loading locations...

Similar Trials